Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-22-3827 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report.
Oncol Lett
August 2024
Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan.
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) has a high recurrence rate, over 70%, and is typically treated with gemcitabine (GEM) chemotherapy, though outcomes are often poor.
- A case study of a 63-year-old woman shows she achieved clinical complete remission for over 7 years after receiving GEM monotherapy, even after developing liver metastases post-surgery.
- Analysis of hENT1 protein levels in tumor tissues suggests that assessing hENT1 expression could help predict the efficacy of GEM treatment in PDAC patients.
IKZF1 deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1 loss on sensitivity to drugs used in contemporary treatment protocols has remained underexplored. Here we show in experimental models and in patients that loss of IKZF1 promotes resistance to cytarabine (AraC), a key component of both upfront and relapsed treatment protocols.
View Article and Find Full Text PDFLarge-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer.
Health Data Sci
January 2024
Department of Bioengineering, Imperial College London, London, UK.
Gemcitabine is a first-line chemotherapy for pancreatic adenocarcinoma (PAAD), but many PAAD patients do not respond to gemcitabine-containing treatments. Being able to predict such nonresponders would hence permit the undelayed administration of more promising treatments while sparing gemcitabine life-threatening side effects for those patients. Unfortunately, the few predictors of PAAD patient response to this drug are weak, none of them exploiting yet the power of machine learning (ML).
View Article and Find Full Text PDFThe prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.
Pancreatology
March 2024
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. Electronic address:
Background: FOLFIRINOX and gemcitabine-nabpaclitaxel (GnP) are standard first-line treatment regimens for advanced pancreatic ductal adenocarcinoma (PDAC). However, currently, there is a lack of predictive biomarkers to aid in the treatment selection. We aimed to explore the prognostic and predictive value of class III β-Tubulin (TUBB3) and human equilibrative nucleoside transporter 1 (hENT1) expression, which have previously been shown to be associated with taxane and gemcitabine resistance in advanced PDAC.
View Article and Find Full Text PDFPutative purine nucleoside interacting residues in the malaria parasite purine uptake transporter PfENT1 are critical for transporter function.
PLoS One
December 2023
Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Malaria remains a major public health threat for billions of people worldwide. Infection with obligate intracellular, unicellular parasites from the genus Plasmodium causes malaria. Plasmodium falciparum causes the deadliest form of human malaria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!